P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy.

Authors:
Sarti AC; Vultaggio-Poma V; Di Virgilio F.

Journal:
Purinergic Signal

Publication Year: 2021

DOI:
10.1007/s11302-021-09783-w

PMCID:
PMC8155152

PMID:
33818742

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Purinergic Signal

Abbreviation: Purinergic Signal

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Biochemistry

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
P2Y<sub>11</sub>/IL-1 receptor crosstalk controls macrophage inflammation: a novel target for anti-…
Klaver D; Thurnher M. (2023) - Transparency Score: 3/6
Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotec…
Fishman P; Stemmer SM; Bareket-Samish A and 2 more (2023) - Transparency Score: 3/6
The P2X7 receptor in mucosal adaptive immunity.
Grassi F; Marino R. (2023) - Transparency Score: 3/6
Burnstock oration - purinergic signalling in kidney transplantation.
Dwyer KM. (2022) - Transparency Score: 3/6
Characterisation of P2Y receptor subtypes mediating vasodilation and vasoconstriction of rat pulmon…
Dales MO; Mitchell C; Gurney AM and 2 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest FDV is a member of the Scientific Advisory Board of Biosceptre Ltd, a Biotech Company involved in the development of P2X7-targeting antibodies. Alba Clara Sarti declares that she has no conflict of interest. Valentina Vultaggio-Poma declares that she has no conflict of interest."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025